CU Hematology Symposia 7.21.22 Dan Pollyea University of Colorado Division of Hematology 53:31 1 year ago 40 Далее Скачать
Addressing whether AML with monocytic features should be considered a distinct clinical entity VJHemOnc – Video Journal of Hematology & HemOnc 1:13 1 year ago 93 Далее Скачать
Venetoclax plus azacitidine for newly diagnosed younger AML VJHemOnc – Video Journal of Hematology & HemOnc 1:29 9 days ago 52 Далее Скачать
Novel treatment paradigms for AML at ASH 2021 VJHemOnc – Video Journal of Hematology & HemOnc 1:01 3 years ago 271 Далее Скачать
The importance of predicting venetoclax response in patients with AML VJHemOnc – Video Journal of Hematology & HemOnc 1:08 1 year ago 322 Далее Скачать
Varied outcomes in patients with AML harboring poor-risk cytogenetics with or without TP53 mutation VJHemOnc – Video Journal of Hematology & HemOnc 1:12 1 year ago 54 Далее Скачать
Comprehensive Molecular Profiling in MDS/AML: The Standard of Care RUNX1 Research Program 33:02 4 months ago 32 Далее Скачать
Omacetaxine and azacitidine for newly diagnosed patients with MDS and excess blasts VJHemOnc – Video Journal of Hematology & HemOnc 1:20 9 days ago 32 Далее Скачать
The potential use of multi-gene molecular MRD testing in AML VJHemOnc – Video Journal of Hematology & HemOnc 1:00 1 year ago 64 Далее Скачать
Comprehensive Molecular Profiling in MDS/AML: The Standard of Care RUNX1 Research Program 53:44 4 months ago 33 Далее Скачать
Treating patients with poor-risk cytogenetics with venetoclax and HMAs VJHemOnc – Video Journal of Hematology & HemOnc 1:50 3 years ago 194 Далее Скачать
IDH mutations in AML treated with venetoclax VJHemOnc – Video Journal of Hematology & HemOnc 2:31 3 years ago 154 Далее Скачать
Glasdegib as maintenance therapy in AML and MDS VJHemOnc – Video Journal of Hematology & HemOnc 1:57 4 years ago 81 Далее Скачать
MDS - AML - 2020 Spring Virtual Conference: When MDS becomes AML - for High-Risk MDS Patients AAMDSIF 50:26 1 year ago 238 Далее Скачать
Exploiting the metabolic vulnerabilities of MDS stem cells VJHemOnc – Video Journal of Hematology & HemOnc 1:34 3 years ago 48 Далее Скачать
IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML VJHemOnc – Video Journal of Hematology & HemOnc 1:48 6 years ago 1 343 Далее Скачать
allo-SCT improves survival following venetoclax and azacitidine therapy in AML VJHemOnc – Video Journal of Hematology & HemOnc 2:16 3 years ago 210 Далее Скачать
Who Polarises? Who Targets? Parties’ Educational Speech over the Long Run The Department of Social Policy, LSE 36:49 2 days ago No Далее Скачать
Targeting MDS stem cells with omacetaxine and azacitidine VJHemOnc – Video Journal of Hematology & HemOnc 1:43 3 years ago 167 Далее Скачать
